# Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

> **NCT02920190** · PHASE4 · WITHDRAWN · sponsor: **University of Miami**

## Conditions studied

- Monoclonal Gammopathies
- Overweight
- Obesity

## Interventions

- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT02920190
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funds to cover the costs of the study medications
- **Last updated:** 2020-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920190, "Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02920190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*